---
title: "《业绩》植华集团中期亏损扩至 847 万元"
description: "植华集团公布 6 月止六个月中期业绩，收益录得 1.47 亿元，按年下降 2.6%。亏损由上年同期 575 万元，扩至 847 万元，每股亏损 0.71 仙。不派息。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/254311780.md"
published_at: "2025-08-24T09:07:11.000Z"
---

# 《业绩》植华集团中期亏损扩至 847 万元

> 植华集团公布 6 月止六个月中期业绩，收益录得 1.47 亿元，按年下降 2.6%。亏损由上年同期 575 万元，扩至 847 万元，每股亏损 0.71 仙。不派息。

植华集团 (01842.HK) 公布 6 月止六个月中期业绩，收益录得 1.47 亿元，按年下降 2.6%。亏损由上年同期 575 万元，扩至 847 万元，每股亏损 0.71 仙。不派息。

### Related Stocks

- [01842.HK - 植华集团](https://longbridge.com/zh-CN/quote/01842.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Amazon, Google And Others Are Pouring $700 Billion Into AI CapEx, Top Analyst Explains Why This Makes It 'Hard' To Bet Against Nvidia | Amazon, Microsoft, Meta, Tesla, Apple, and Google are set to invest nearly $700 billion in AI-driven capital expenditure | [Link](https://longbridge.com/zh-CN/news/275700100.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| Prediction: This AI Stock Will Soar After Feb. 25. Here's Why. | Nvidia (NVDA) shares have faced a 2% decline over the past three months due to geopolitical tensions and concerns about  | [Link](https://longbridge.com/zh-CN/news/275701772.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-CN/news/275851575.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。